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S U M M A R Y
Objectives: The real-time PCR assay is the most sensitive test for screening and diagnosing sexually
transmitted infections (STIs) and has made diagnosing these infections easier for clinicians. The aim of
this study was to investigate the reliability, accuracy, and usefulness of the real-time multiplex PCR assay
for the detection of seven sexually transmitted microorganisms in clinical samples.
Methods: A total of 897 specimens from 365 symptomatic patients and 532 asymptomatic volunteers
were collected over a 10-month period. A total of 696 subjects provided 50 ml of ﬁrst-voided urine as
samples, and 201 female patients provided endocervical swab specimens. Chlamydia trachomatis,
Neisseria gonorrhoeae, Trichomonas vaginalis, Mycoplasma genitalium, Mycoplasma hominis, Ureaplasma
urealyticum, and Ureaplasma parvum were tested for using ﬁve diagnostic methods: multiplex real-time
PCR (AnyplexTM II), multiplex PCR (Seeplex1), strand displacement ampliﬁcation (SDA, BD ProbeTecTM
ET), PCR (AmpliSens1), and a commercially available Mycoplasma IST 2 Kit.
Results: Multiplex real-time PCR (AnyplexTM II) showed outstanding results in all ﬁelds, particularly
sensitivity and speciﬁcity, compared with other diagnostic tools. This method yielded 100% sensitivity
and high speciﬁcity for the detection of C. trachomatis, N. gonorrhoeae, T. vaginalis, M. genitalium, and M.
hominis. It was also useful for discriminating between U. urealyticum and U. parvum.
Conclusions: Multiplex real-time PCR was found to be an equivalent or superior modality for the
diagnosis of STIs. It could be a cost-effective and rapid diagnostic tool for the simultaneous detection of
multiple STI microorganisms.
 2013 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
Sexually transmitted infections (STIs) are important individual,
medical, social, and economic issues. The World Health Organiza-
tion (WHO) estimates that 498.9 million new cases of syphilis,
gonorrhea, chlamydia, and trichomoniasis occurred worldwide in
2008.1 The reported prevalences of syphilis, gonorrhea, chlamydia,
and trichomoniasis are 0.37%, 0.43%, 5.58%, and 2.4%, respectively,
in the Republic of Korea.2,3 It is important to increase vigilance and
to recognize that STIs are often asymptomatic or cause nonspeciﬁc* Corresponding author. Tel.: +82 31 249 8221; fax: +82 31 253 0949.
E-mail address: dcpark@catholic.ac.kr (D.C. Park).
1201-9712/$36.00 – see front matter  2013 International Society for Infectious Disea
http://dx.doi.org/10.1016/j.ijid.2013.07.011symptoms, that STIs can increase the infectiousness of HIV, and
that regular testing for STIs is crucial.4 Nucleic acid ampliﬁcation
tests (NAATs) are the most sensitive tests for STI screening and
diagnosis. NAATs are more sensitive than the previously available
diagnostic tests (e.g., culture, antigen detection, and nucleic acid
hybridization) by approximately 20–30%.5 NAATs provide an
improvement in medical screening for STIs6 because they can be
used with noninvasively collected specimens such as ﬁrst-voided
urine samples and self- or clinician-collected vaginal swabs. More
recently, the multiplex PCR assay has made it convenient for
clinicians in many clinical ﬁelds to test for multiple causative
organisms simultaneously. The multiplex PCR assay is a cost-
effective diagnostic test because it allows for faster detection and a
reduction in labor and reagent costs.7–9ses. Published by Elsevier Ltd. All rights reserved.
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detection of an ampliﬁed DNA target in the same step. Compared
with conventional PCR, real-time PCR is cost-effective because it
improves the detection sensitivity, decreases the ampliﬁcation
time, and simpliﬁes downstream processing.10 There are possible
limitations in multiplexing. One possible limitation is PCR drift as a
result of stochastic ﬂuctuation in the interactions of PCR reagents,
particularly in the early cycles, which could arise in the presence of
very low template concentrations or through the assay design.11
The reliability and accuracy of multiplex PCR for STIs have not been
evaluated thoroughly. The aim of this study was to evaluate the
performance and usefulness of real-time PCR assays for the
detection of seven sexually transmitted microorganisms in clinical
samples.
2. Patients and methods
2.1. Study population and clinical specimens
The study population consisted of two groups: symptomatic
patients and asymptomatic volunteers. Three hundred sixty-ﬁve
patients who were suspected of having an STI and who visited
urology or gynecology hospitals in metropolitan areas were
enrolled in the symptomatic patients group. Five hundred
thirty-two volunteers who visited the Korean Industrial Health
Association for a health examination and signed the informed
consent form for this study were enrolled in the asymptomatic
volunteers group. Over a period of 10 months, 897 specimens
(from 365 symptomatic patients and 532 asymptomatic volun-
teers) were collected and tested. The specimens included 510 ﬁrst-
voided urine samples from men, 186 ﬁrst-voided urine samplesFigure 1. Flow chart showing the popfrom women, and 201 endocervical swabs from women. The male
participants and female volunteers were asked to provide 50 ml of
ﬁrst-voided urine (at least 2 h after previous urination) in a sterile
50-ml screw-cap plastic bottle. The endocervical swab specimens
from female participants were collected by doctors, who followed
the regular procedures for speculum examination and used
manufactured collection kits. The specimens were immediately
placed in a cooler and transported to the Central Diagnostic
Laboratory in Seoul (Department of Laboratory Medicine, Chung-
Ang University Hospital). The specimens were transported without
added transport medium and were refrigerated and examined
within 48 h.
2.2. Laboratory tests
Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas
vaginalis, Mycoplasma genitalium, Mycoplasma hominis, Ureaplasma
urealyticum, and Ureaplasma parvum were detected by four NAATs:
multiplex real-time PCR (AnyplexTM II, Seegene, Seoul, Korea),
multiplex PCR (Seeplex1, Seegene, Seoul, Korea), strand displace-
ment ampliﬁcation (SDA) (BD ProbeTecTM ET, Becton–Dickinson
Microbiology System, Sparks, MD, USA), and PCR (AmpliSens1, PCR
Kit, InterLabService Ltd, Moscow, Russia), and using a commer-
cially available Mycoplasma IST 2 Kit (bioMe´rieux, Marcy l’Etoile,
France) (Figure 1).
2.3. Nucleic acid ampliﬁcation tests (NAATs)
2.3.1. Pretreatment of clinical specimens and DNA extraction
The swab specimens (approximately 2–3 ml) in the collection
tubes were equilibrated to room temperature and mixed byulation and samples in the study.
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carefully to avoid contamination; 1-ml mixed specimens were
transferred to 1.5-ml microcentrifuge tubes and the tubes were
centrifuged at 15 000  g (13 000 rpm). The supernatant was
discarded and the pellet was resuspended in 1 ml of
1  phosphate-buffered saline (PBS) by vortexing thoroughly to
re-dissolve and disperse the sample. The urine specimens
(approximately 10 ml) were equilibrated to room temperature
and centrifuged at 5000  g for 15 min. The supernatant was
discarded and the pellet was resuspended in 1 ml 1  PBS before
DNA extraction. The DNA was extracted from the pretreated
specimens (swab or urine) using the QIAamp DNA Mini Kit
(Qiagen, Hilden, Germany), in accordance with the manufacturer’s
instructions.
2.3.2. Multiplex real-time PCR (AnyplexTM II STI-7 Detection Kit)
Real-time PCR ampliﬁcation for seven microorganisms (C.
trachomatis, N. gonorrhoeae, T. vaginalis, M. genitalium, M.
hominis, U. urealyticum, and U. parvum) was performed using
the AnyplexTM II STI-7 Detection Kit (Seegene, Seoul, Korea), in
accordance with the manufacturer’s protocol, in a CFX96 real-
time thermocycler  (Bio-Rad, Hercules, CA, USA). Each PCR was
performed in 5 ml of extracted DNA, 4x STI-7 TOM, and Anyplex
PCR Mix in a 20-ml reaction. The thermal cycle conditions
consisted of an initial incubation at 50 8C for 4 min to activate the
UDG system and prevent contamination, and pre-denaturation
at 95 8C for 15 min, followed by 50 cycles of alternating
incubations: 95 8C for 30 s, 60 8C for 1 min, and 72 8C for 30 s.
The melting temperature was analyzed by increasing the
reaction temperature from 55 8C to 85 8C (5 s/0.5 8C). The whole
process control was added to the samples immediately before
the DNA extraction to conﬁrm the DNA extraction and PCR
inhibition.
2.3.3. Multiplex PCR (Seeplex1 STD6 ACE Detection Kit)
PCR ampliﬁcation was performed using the Seeplex1 STD6 ACE
Detection Kit (Seegene, Seoul, Korea), in accordance with the
manufacturer’s protocol. The kit contains six pairs of primers that
are speciﬁcally designed from highly conserved regions of genetic
sequences for six microorganisms (N. gonorrhoeae, C. trachomatis,
T. vaginalis, M. genitalium, M. hominis, and U. urealyticum) using
Seegene DPO technology.6 An internal control is present in the PCR
mix for the detection of PCR inhibiting conditions (981 bp). For the
negative control, sterile deionized water was used instead of DNA
as the PCR template. To verify the integrity of the primers used in
the PCR assay, positive DNA controls from the kit were assayed in
the presence of all primer pairs. The ampliﬁed fragments were
separated by agarose gel electrophoresis and identiﬁed by
ethidium bromide staining.
2.3.4. Strand displacement ampliﬁcation (SDA) (BD ProbeTecTM)
The BD ProbeTecTM (Becton–Dickinson Microbiology System,
Sparks, MD, USA) utilizes SDA technology as the ampliﬁcation
method and ﬂuorescent energy transfer (ET) as the detection
method to test for C. trachomatis and N. gonorrhoeae. This semi-
automated system is based on the simultaneous ampliﬁcation and
detection of the target DNA, using ampliﬁcation primers directed
against the plasmid DNA and a ﬂuorescently labeled detector
probe. Positive and negative controls for specimen processing are
included in the kit, with an ampliﬁcation control to monitor assay
inhibition. The assay was performed in accordance with the
manufacturer’s instructions. The presence or absence of C.
trachomatis and N. gonorrhoeae is determined by relating the
method-other-than-acceleration (MOTA) scores for the specimen
to pre-determined cutoff values. The results with a MOTA value
between 2000 and 20 000 (low positive) were rechecked, and thespecimens that showed a ﬁnal score of less than 2000 were
determined to be negative in this study.12
2.3.5. AmpliSens1 PCR Kit
For the PCR ampliﬁcation of T. vaginalis and M. genitalium, each
PCR kit (AmpliSens1 Trichomonas vaginalis-EPH PCR Kit and
AmpliSens1 Mycoplasma genitalium-EPH PCR Kit; InterLabService
Ltd, Moscow, Russia) was used in accordance with the manu-
facturer’s protocol. A total of 10 ml of the DNA samples was added
to the PCR pre-mix in a 25-ml reaction. One drop (25 ml) of mineral
oil was added to each PCR reaction mixture to prevent
contamination during the PCR reaction. The analysis of each
ampliﬁcation product was performed by separating the DNA
fragment in agarose gel.
2.4. Mycoplasma IST 2 Kit
The identiﬁcation of M. hominis and U. urealyticum was
performed with a commercially available Mycoplasma IST 2 Kit
(bioMe´rieux, Marcy l’Etoile, France). The Mycoplasma IST 2 Kit
combines a selective culture broth with a strip containing 22 tests.
A positive test is indicated by a change of broth color from yellow
to red as a result of the phenol red indicator in the broth (urea for U.
urealyticum and arginine for M. hominis). Approximately 500 ml of
urine and 100 ml of an endocervical swab specimen (and two micro
bank beads) were inoculated into the R1 solution, which was
combined with a vial of R2 and vortexed. Fifty-ﬁve microliters of
the solution was dispensed into each of the 22 test wells on the
strip. Two drops of mineral oil were added to each well. The strips
were incubated at 37 8C for 24–48 h. Colony forming units of 104/
ml were considered a positive result for M. hominis and U.
urealyticum infection.
2.5. Analysis of results
All specimens were tested in parallel using four NAATs and one
Mycoplasma detection kit (Figure 1). An expanded gold standard,
which was deﬁned for the determination of true-positive speci-
mens, was established to evaluate the new multiplex real-time PCR
assay.13 The results were considered true positives for C.
trachomatis, N. gonorrhoeae, T. vaginalis, and M. genitalium if they
were positive according to any of the two NAATs. For M. hominis
and U. urealyticum, any two positive results (a positive for either of
the detection kits and a positive for one of the NAATs, or two
positive for the NAATs) were considered a true-positive. The
results of U. parvum were not analyzed because only one NAAT was
available for U. parvum and the Mycoplasma IST 2 Kit is not able to
differentiate between U. parvum and U. urealyticum.
The sensitivity and speciﬁcity of each test method for each
microorganism were calculated for the specimens tested in
parallel. The positive predictive value (PPV) and negative predic-
tive value (NPV) were calculated for all specimens.
2.6. Quality control
Published guidelines were followed to guard against nuclease
and nucleic acid contamination,14,15 including the maintenance of
a strict physical separation between the PCR setup and analysis,
the use of sterile ﬁlter tips, and the regular decontamination of all
surfaces with hypochlorite.16 The assay controls included a
negative extraction control, which was derived from pooled
negative specimens, and a negative ampliﬁcation control com-
prised of RNase–DNase-free sterile deionized water. All the tests
were performed blind at the central laboratory. Results were
recorded on pre-designed results sheets, scanned, and returned to
the organizing researchers for comparison and analysis.
Table 1
Distribution of organisms in the positive clinical samples. The summation of microorganism distribution (%) exceeds 100% because multiple microorganism positivity was
counted individually
Organism Total No. (N = 897) Female; swabs (n = 201) Female; urine (n = 186) Male; urine (n = 510)
No. positive Incidence (%) No. positive Incidence (%) No. positive Incidence (%)
Chlamydia trachomatis 72 8 4.0 8 4.3 56 11.0
Neisseria gonorrhoeae 37 3 1.5 4 2.2 30 5.9
Trichomonas vaginalis 8 2 1.0 1 0.5 5 1.0
Mycoplasma genitalium 30 8 4.0 6 3.2 16 3.1
Mycoplasma hominis 68 30 14.9 22 11.8 16 3.1
Ureaplasma urealyticum 197 81 40.3 45 24.2 71 13.9
Ureaplasma parvum 296 106 52.7 103 55.4 87 17.1
All negative results 445 71 35.3 62 33.3 312 61.2
Single microorganism detected 257 51 25.4 71 38.2 135 26.5
Multiple microorganisms detected 195 79 39.3 53 28.5 63 12.4
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The Institutional Review Board of The Catholic University of
Korea College of Medicine approved the study protocol, and all
subjects provided written informed consent to participate in this
study (XC12OIMI0003 V).
3. Results
3.1. Clinical incidence of seven sexually transmitted infections in 897
subjects
The distribution of the microorganisms in the clinical speci-
mens by source is shown in Table 1. The total group of 897 patients
consisted of 445 patients who had negative test results, 257
patients who were single microorganism positive, and 195 patientsTable 2
Numbers of positive and negative results for Chlamydia trachomatis and comparisons w
Test Expanded standarda Sensi
(95% 
Positive Negative
PCR (AnyplexTM II) 100.0
Positive 62 0 (100.
Negative 0 835
PCR (Seeplex1) 96.8 
Positive 60 5 (92.5
Negative 2 830
SDA (BD ProbeTecTM) 83.9 
Positive 52 5 (74.4
Negative 10 830
PCR, polymerase chain reaction; SDA, strand displacement ampliﬁcation; PPV, positive
a Two positive NAATs.
Table 3
Numbers of positive and negative results for Neisseria gonorrhoeae and comparisons w
Test Expanded standarda Sensi
(95% 
Positive Negative
PCR (AnyplexTM II) 100.0
Positive 27 7 (100.
Negative 0 863
PCR (Seeplex1) 100.0
Positive 27 3 (100.
Negative 0 867
SDA (BD ProbeTecTM) 88.9 
Positive 24 1 (76.6
Negative 3 869
Culture (T–M agar) 81.5 
Positive 22 0 (65.3
Negative 5 870
PCR, polymerase chain reaction; SDA, strand displacement ampliﬁcation; PPV, positive p
interval.
a Either (1) culture positive, or (2) two of the NAATs positive.who were positive for multiple microorganisms. One-third of the
female patients had all negative results (vaginal swab 35.3%, urine
33.3%), whereas 61.2% of the male patients had all negative results.
The most prevalent microorganism was U. parvum (296 cases). U.
urealyticum, C. trachomatis, and M. hominis were detected, in that
order. U. parvum was the most frequently detected microorganism
in the female patients (50%), while it was detected in only 17.1% of
the male patients. C. trachomatis and N. gonorrhoeae were more
frequently detected in the male patients than in the female
patients.
3.2. Clinical sensitivity, speciﬁcity, PPV, and NPV
The sensitivity, speciﬁcity, PPV, and NPV of each diagnostic
assay using the expanded gold standard as reference are shown in
Tables 2–7. When the expanded gold standard was applied,ith the expanded standard
tivity (%)
CI)
Speciﬁcity (%)
(95% CI)
PPV (%) NPV (%)
 100.0 100.0 100.0
0–100.0) (100.0–100.0)
99.4 92.3 99.8
–100.0) (98.9–99.9)
99.4 91.2 98.8
–93.4) (98.9–99.9)
 predictive value; NPV, negative predictive value; CI, conﬁdence interval.
ith the expanded standard
tivity (%)
CI)
Speciﬁcity (%)
(95% CI)
PPV (%) NPV (%)
 99.2 79.4 100.0
0–100.0) (98.6–99.8)
 99.7 90.0 100.0
0–100.0) (99.3–100.0)
99.9 96.0 99.7
–100.0) (99.7–100.0)
100.0 100.0 99.4
–97.7) (100.0–100.0)
redictive value; NPV, negative predictive value; T–M, Thayer–Martin; CI, conﬁdence
Table 4
Numbers of positive and negative results for Trichomonas vaginalis and comparisons with the expanded standard
Test Expanded standarda Sensitivity (%)
(95% CI)
Speciﬁcity (%)
(95% CI)
PPV (%) NPV (%)
Positive Negative
PCR (AnyplexTM II) 100.0 99.9 75.0 100.0
Positive 3 1 (100.0–100.0) (99.7–100.0)
Negative 0 893
PCR (Seeplex1) 100.0 100.0 100.0 100.0
Positive 3 0 (100.0–100.0) (100.0–100.0)
Negative 0 894
PCR (AmpliSens1) 100.0 99.4 37.5 100.0
Positive 3 5 (100.0–100.0) (98.9–99.9)
Negative 0 889
PCR, polymerase chain reaction; PPV, positive predictive value; NPV, negative predictive value; CI, conﬁdence interval.
a Two positive NAATs.
Table 5
Numbers of positive and negative results for Mycoplasma genitalium and comparisons with the expanded standard
Test Expanded standarda Sensitivity (%)
(95% CI)
Speciﬁcity (%)
(95% CI)
PPV (%) NPV (%)
Positive Negative
PCR (AnyplexTM II) 100.0 100.0 100.0 100.0
Positive 24 0 (100.0–100.0) (100.0–100.0)
Negative 0 873
PCR (Seeplex1) 91.7 99.8 91.7 99.8
Positive 22 2 (80.7–100.0) (99.5–100.0)
Negative 2 871
PCR (AmpliSens1) 100.0 99.3 80.0 100.0
Positive 24 6 (100.0–100.0) (98.7–99.9)
Negative 0 867
PCR, polymerase chain reaction; PPV, positive predictive value; NPV, negative predictive value; CI, conﬁdence interval.
a Two positive NAATs.
Table 6
Numbers of positive and negative results for Mycoplasma hominis and comparisons with the expanded standard
Test Expanded standarda Sensitivity (%)
(95% CI)
Speciﬁcity (%)
(95% CI)
PPV (%) NPV (%)
Positive Negative
PCR (AnyplexTM II) 100.0 99.3 88.7 100.0
Positive 47 6 (100.0–100.0) (98.7–99.9)
Negative 0 844
PCR (Seeplex1) 100.0 98.9 83.9 100.0
Positive 47 9 (100.0–100.0) (98.2–99.6)
Negative 0 841
Mycoplasma IST 2 Kit 44.7 99.6 87.5 97.0
Positive 21 3 (24.8–64.6) (99.2–100.0)
Negative 26 847
PCR, polymerase chain reaction; PPV, positive predictive value; NPV, negative predictive value; CI, conﬁdence interval.
a Either (1) detection kit positive and one positive NAAT, or (2) two positive NAATs.
Table 7
Numbers of positive and negative results for Ureaplasma urealyticum and comparisons with the expanded standard
Test Expanded standarda Sensitivity (%)
(95% CI)
Speciﬁcity (%)
(95% CI)
PPV (%) NPV (%)
Positive Negative
PCR (AnyplexTM II) 97.8 99.3 93.5 99.8
Positive 87 6 (94.8–100.0) (98.7–99.9)
Negative 2 802
PCR (Seeplex1) 100.0 99.4 94.7 100.0
Positive 89 5 (100.0–100.0) (98.9–99.9)
Negative 0 803
Mycoplasma IST 2 Kit 44.9 87.9 29.0 93.5
Positive 40 98 (36.6–53.2) (85.6–90.2)
Negative 49 710
PCR, polymerase chain reaction; PPV, positive predictive value; NPV, negative predictive value; CI, conﬁdence interval.
a Either (1) detection kit positive and one positive NAATs, or (2) two positive NAATs.
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The two other assays had greater than 90% PPV and NPV. For N.
gonorrhoeae, AnyplexTM II and Seeplex1 showed 100% sensitivity,
and BD ProbeTecTM showed 80% sensitivity. This difference in thesensitivity is likely attributable to very low positivity being
considered negativity in the BD ProbeTecTM because the BD
ProbeTecTM analyzes the results using the MOTA score (Tables 2
and 3).
Table 8
Distribution of Mycoplasma IST 2 Kit results
Total No.
(N = 897)
AnyplexTM II
UU-posa UU-pos UU-neg UU-neg
UP-posb UP-neg UP-pos UP-neg
Mycoplasma IST 2 Kit
Positive 138 14 24 96 4
Negative 759 10 45 177 527
UU, Ureaplasma urealyticum; UP, Ureaplasma parvum.
a Two positive NAATs.
b AnyplexTM II PCR positive.
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the expanded gold standard, the three assays showed greater than
90% sensitivity and speciﬁcity. AnyplexTM II and AmpliSens1
showed low PPV for T. vaginalis (75.0% and 37.5%, respectively),
which is likely attributable to errors that occur because of the small
number of positive cases used when diagnosing a disease that has
very low prevalence (Tables 4 and 5).
In the diagnostic assay of M. hominis and U. urealyticum using
(1) a detection kit positive and one of the NAATs positive, or (2) two
of the NAATs positive, as the expanded gold standard, the
sensitivity and speciﬁcity were shown to be lower for the
Mycoplasma IST 2 Kit than for AnyplexTM II and Seeplex1 (Tables
6 and 7). A direct comparison is difﬁcult due to the differences
between the diagnostic methods and principles in the NAATs and
those in the commercial culture kit. The aforementioned difference
is likely to be attributable to weak positivity being considered
negativity in the Mycoplasma IST 2 Kit, in which 104 colony-
forming units/ml is considered a positive result.
In the diagnostic assay for U. urealyticum, the PPV was shown to
be 29.0% for the Mycoplasma IST 2 Kit. It is likely that a signiﬁcant
portion of microorganisms detected as U. parvum by AnyplexTM II
were detected as U. urealyticum in the Mycoplasma IST 2 Kit. This
explanation is reasonable because 96 (35.1%) of the cases
determined to be U. urealyticum-negative and U. parvum-positive
using AnyplexTM II, were determined to be U. urealyticum-positive
using the Mycoplasma IST 2 Kit (Table 8).
4. Discussion
This study was conducted to compare the diagnostic perfor-
mance of a recently developed real-time multiplex PCR to that of
the conventional methods used for the multiple detection of
bacterial STIs. We analyzed the sensitivity and speciﬁcity of the
methods available for the diagnosis of seven sexually transmitted
microorganisms comparatively. A combination test was performed
on the specimens, and the expanded gold standard was used to
assess the new diagnostic test. Although this assessment method
increases the workload and costs because more tests are conducted
on the specimens, it has been known to reduce data bias if no
perfect gold standard is available.13,17
In the detection of C. trachomatis, due to the technical difﬁculty
resulting from the necessity of immediately inoculating specimens
into cell lines after specimen collection, the culture test has a low
sensitivity of 50% and is no longer used clinically; as a result NAATs
have been used as standard tests.18 In the detection of N.
gonorrhoeae, the culture test using Thayer–Martin agar has been
used as a standard method. Due to difﬁculties in specimen
collection, transfer, and storage, this test has a low sensitivity and
is unsuitable for screening.17 Except for special circumstances (e.g.,
measuring antimicrobial sensitivity), NAATs have become the tests
of choice and are used instead of the culture test. In the detection of
C. trachomatis and N. gonorrhoeae, the two most common
pathogens of bacterial STIs, NAATs have been applied predomi-nantly in the form of combination-type commercial kits that can
detect pathogens simultaneously, or multiplex-type commercial
kits that can detect additional pathogens. In this study, real-time
PCR and PCR had 100% and 96.8% sensitivity, respectively, for C.
trachomatis, and 100% sensitivity for N. gonorrhoeae. SDA had 83.9%
and 88.9% sensitivity for C. trachomatis and N. gonorrhoeae,
respectively, which is relatively low. This difference in the
sensitivity is likely attributable to the fact that very low positivity
is considered negativity in SDA because SDA (BD ProbeTecTM ET)
analyzes the results using the MOTA score. No deﬁnite reason for
the low sensitivity has been presented. Other studies have shown
similar results, conﬁrming that the NAATs do not always produce
the same results for the same specimens.19,20
T. vaginalis is a parasitic protozoan and has a diverse prevalence
of 0.9–18.2% in Asian countries,21–23 with a reported prevalence of
1.1–2.4% in asymptomatic individuals in Korea.3,24 In this study, T.
vaginalis had a very low prevalence of 0.9%, which is likely
attributable to the high male circumcision rate in Korea.25,26 Due to
its low prevalence, NAATs may have a low PPV for T. vaginalis.27 In
this study, AnyplexTM II and AmpliSens1 had 75.0% and 37.5% PPV,
respectively, for T. vaginalis. This bias should be considered when
diagnosing T. vaginalis in regions with a low prevalence.
With the recent accumulation of considerable evidence on M.
genitalium, this organism has been recognized as a pathogen of
acute and chronic urethritis in males.28 It has also been reported to
be associated with female cervicitis and pelvic inﬂammatory
disease.29 Proactive diagnosis and treatment of M. genitalium is
required. The detection of M. genitalium via culture is no longer
used in routine clinical practice because it takes many weeks and
presents technical difﬁculties.30 Due to cross-reactivity with M.
pneumoniae, it is not appropriate to use a serological test to
diagnose M. genitalium. NAATs are currently recognized as the tools
available for detecting M. genitalium. Several real-time PCRs have
been introduced to detect M. genitalium. In such methods, the
quantiﬁcation of M. genitalium DNA has been reported to be useful
in judging the treatment efﬁcacy and for assessing the DNA load of
clinical specimens.31,32 This method could provide vital informa-
tion in the detection of M. genitalium, which has no established
therapeutic agent and has non-distinct symptoms. In this study,
the three NAATs had high sensitivity and speciﬁcity. Real-time PCR
had 100% sensitivity and speciﬁcity and showed robustness in
various specimens.
In addition to M. genitalium, M. hominis and Ureaplasma species
are included in genital mycoplasmas. In a study conducted in the
USA, M. hominis and Ureaplasma species were detected in 21–53%
and 40–80% of asymptomatic and sexually active women,
respectively, and their prevalences were slightly lower in men
than in women.33 The results of this study are consistent with
those of a previous study conducted in the USA (Table 1). As the
high detection rates of M. hominis and Ureaplasma species might
have been caused by commensalism and infection, their roles as
pathogens is controversial. Much evidence shows that M. hominis
detected in urethral specimens is not associated with male
urethritis. M. hominis was shown to act as a pathogen in 5% of
upper urinary tracts of patients with acute pyelonephritis,34 and
was shown to act as a co-factor of bacterial vaginosis.35
Ureaplasma species, which were formerly known as U.
urealyticum biovars 1 and 2, were identiﬁed as separate species
– U. urealyticum (biovar 2) and U. parvum (biovar 1) – by PCR. U.
urealyticum has been reported to be a pathogen of male urethritis36
and is known to cause infertility by affecting sperm quality.37 U.
parvum has been reported to be associated with chorioamnionitis,
fetal morbidity, and fetal mortality in pregnant women,38 but its
role as an STI pathogen is unclear. The discrimination of U.
urealyticum and U. parvum is important in the diagnosis of STIs
because unnecessary treatment might be carried out if U. parvum,
H.-S. Choe et al. / International Journal of Infectious Diseases 17 (2013) e1134–e1140e1140most of which are colonized as commensals, is mistakenly
considered to be U. urealyticum. In this study, it was impossible
to differentiate between U. urealyticum and U. parvum using the
Mycoplasma IST 2 Kit. A signiﬁcant segment of the U. urealyticum
positivity identiﬁed via the Mycoplasma IST 2 Kit was revealed to
be U. parvum positivity via PCR (Table 8). It is necessary to conduct
more analytical research on the detection and discrimination of
Ureaplasma species.
One of the most important features of real-time PCR is
quantiﬁcation. Unlike bacterial culture, in which only viable
bacteria can be quantiﬁed, real-time PCR can quantify both viable
and nonviable bacteria. The quantiﬁcation of the bacterial load in
clinical specimens can provide a critical clue in discriminating
between infection and commensalism, which leads to an evalua-
tion of the patient’s prognosis by determining disease severity and
assessing treatment efﬁcacy.39,40 The determination of the
bacterial load using real-time PCR could be used as a useful
marker in the diagnosis of STIs. Further study is required to explore
this possibility.
In conclusion, the performance of the multiplex real-time PCR
was equal or superior to that of the NAATs and detection kits that
are currently used for STI diagnoses. The multiplex real-time PCR is
cost-saving because it can rapidly detect multiple microorganisms
simultaneously via its multiplex function, and it is expected that it
will be used as a standard diagnostic test for STIs in the near future.
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